Actuate Therapeutics Common Stock Net Income
| ACTU Stock | 5.39 0.08 1.51% |
As of the 27th of January, Actuate Therapeutics shows the Risk Adjusted Performance of (0.06), standard deviation of 3.98, and Mean Deviation of 3.04. Actuate Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Actuate Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Actuate Therapeutics' valuation are summarized below:There are currently eighty-five fundamental signals for Actuate Therapeutics Common that can be evaluated and compared over time across rivals. All traders should validate Actuate Therapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to drop to about 102 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -24.6 M | -25.8 M | |
| Net Loss | -24.6 M | -25.8 M | |
| Net Loss | (1.61) | (1.69) | |
| Net Income Per E B T | 0.90 | 0.80 |
Actuate | Net Income | Build AI portfolio with Actuate Stock |
Latest Actuate Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Actuate Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Actuate Therapeutics financial statement analysis. It represents the amount of money remaining after all of Actuate Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Actuate Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Actuate Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (27.29 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Actuate Net Income Regression Statistics
| Arithmetic Mean | (21,437,858) | |
| Coefficient Of Variation | (11.37) | |
| Mean Deviation | 1,955,288 | |
| Median | (20,159,401) | |
| Standard Deviation | 2,436,669 | |
| Sample Variance | 5.9T | |
| Range | 7.1M | |
| R-Value | (0.72) | |
| Mean Square Error | 3.1T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | (346,729) | |
| Total Sum of Squares | 95T |
Actuate Net Income History
Other Fundumenentals of Actuate Therapeutics
Actuate Therapeutics Net Income component correlations
Actuate Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Actuate Therapeutics is extremely important. It helps to project a fair market value of Actuate Stock properly, considering its historical fundamentals such as Net Income. Since Actuate Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Actuate Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Actuate Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actuate Therapeutics. If investors know Actuate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actuate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Actuate Therapeutics is measured differently than its book value, which is the value of Actuate that is recorded on the company's balance sheet. Investors also form their own opinion of Actuate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Actuate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actuate Therapeutics' market value can be influenced by many factors that don't directly affect Actuate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actuate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actuate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actuate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Actuate Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Actuate Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Actuate Therapeutics.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Actuate Therapeutics on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Actuate Therapeutics Common or generate 0.0% return on investment in Actuate Therapeutics over 90 days. Actuate Therapeutics is related to or competes with Seres Therapeutics, Spero Therapeutics, VistaGen Therapeutics, Elicio Therapeutics, Nkarta, Vor Biopharma, and Alector. Actuate Therapeutics is entity of United States More
Actuate Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Actuate Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Actuate Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 20.01 | |||
| Value At Risk | (6.74) | |||
| Potential Upside | 5.4 |
Actuate Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Actuate Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Actuate Therapeutics' standard deviation. In reality, there are many statistical measures that can use Actuate Therapeutics historical prices to predict the future Actuate Therapeutics' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (0.24) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Actuate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Actuate Therapeutics January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.23) | |||
| Mean Deviation | 3.04 | |||
| Coefficient Of Variation | (1,022) | |||
| Standard Deviation | 3.98 | |||
| Variance | 15.8 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (0.24) | |||
| Maximum Drawdown | 20.01 | |||
| Value At Risk | (6.74) | |||
| Potential Upside | 5.4 | |||
| Skewness | 0.2515 | |||
| Kurtosis | 0.6831 |
Actuate Therapeutics Backtested Returns
Actuate Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0543, which signifies that the company had a -0.0543 % return per unit of risk over the last 3 months. Actuate Therapeutics Common exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Actuate Therapeutics' Risk Adjusted Performance of (0.06), standard deviation of 3.98, and Mean Deviation of 3.04 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.66, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Actuate Therapeutics will likely underperform. At this point, Actuate Therapeutics has a negative expected return of -0.22%. Please make sure to confirm Actuate Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Actuate Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.58 |
Good reverse predictability
Actuate Therapeutics Common has good reverse predictability. Overlapping area represents the amount of predictability between Actuate Therapeutics time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Actuate Therapeutics price movement. The serial correlation of -0.58 indicates that roughly 58.0% of current Actuate Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.58 | |
| Spearman Rank Test | -0.51 | |
| Residual Average | 0.0 | |
| Price Variance | 0.33 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Actuate Therapeutics Common reported net income of (27.29 Million). This is 107.99% lower than that of the Biotechnology sector and 138.95% lower than that of the Health Care industry. The net income for all United States stocks is 104.78% higher than that of the company.
Actuate Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Actuate Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Actuate Therapeutics could also be used in its relative valuation, which is a method of valuing Actuate Therapeutics by comparing valuation metrics of similar companies.Actuate Therapeutics is currently under evaluation in net income category among its peers.
Actuate Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Actuate Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Actuate Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Actuate Fundamentals
| Return On Asset | -3.49 | ||||
| Current Valuation | 129.97 M | ||||
| Shares Outstanding | 23.24 M | ||||
| Shares Owned By Insiders | 16.14 % | ||||
| Shares Owned By Institutions | 49.72 % | ||||
| Number Of Shares Shorted | 529.79 K | ||||
| Price To Book | 11.29 X | ||||
| EBITDA | (25.16 M) | ||||
| Net Income | (27.29 M) | ||||
| Total Debt | 404.99 K | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (21.84 M) | ||||
| Short Ratio | 7.32 X | ||||
| Earnings Per Share | (3.11) X | ||||
| Target Price | 26.75 | ||||
| Number Of Employees | 10 | ||||
| Market Capitalization | 136.67 M | ||||
| Total Asset | 9.32 M | ||||
| Retained Earnings | (132.38 M) | ||||
| Working Capital | 405.4 K | ||||
| Net Asset | 9.32 M |
About Actuate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Actuate Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Actuate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Actuate Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.